newsfilter
← Latest News
GlobeNewswire·

LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointChina National Medical Products Administration (NMPA) accepted mavacamten New Drug